Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways

Statins inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme and are the most widely used medication for hypercholesterolemia. Previous studies on the metabolite signature of simvastatin treatment have included only a small number of metabolites. We performed a high-throughput liquid chromato...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes Silva, Lilian, Ravi, Rowmika, Vangipurapu, Jagadish, Laakso, Markku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414498/
https://www.ncbi.nlm.nih.gov/pubmed/36005625
http://dx.doi.org/10.3390/metabo12080753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414498/
https://www.ncbi.nlm.nih.gov/pubmed/36005625
http://dx.doi.org/10.3390/metabo12080753

Ejemplares similares